Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mobius Scientific is developing a novel biologic platform aimed at treating the root causes of chronic diseases, starting with retinal health and age-related macular degeneration. The company’s approach targets underlying lipid accumulation, which is implicated in both eye disease and broader chronic conditions. Early results from founder Dr. Nehal Mehta’s prior work suggest promise in improving vascular inflammation through similar therapeutic strategies, but no published clinical trial outcomes for Mobius programs are available yet.[1][2][3][5]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mobius Scientific.